Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer

BACKGROUND: Doxorubicin is one of the most commonly used chemotherapeutic drugs for breast cancer; however, its use is limited by drug resistance and side-effects. We hypothesized that adding FTY720, a sphingosine-1- phosphate (S1P) receptor functional antagonist, to doxorubicin would potentiate its...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Surg Res
Prif Awduron: Katsuta, Eriko, Yan, Li, Nagahashi, Masayuki, Raza, Ali, Sturgill, Jamie L., Lyon, Debra E., Rashid, Omar M., Hait, Nitai C., Takabe, Kazuaki
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2017
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5661979/
https://ncbi.nlm.nih.gov/pubmed/29078883
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jss.2017.05.101
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg